Skip to content
Open access

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination

Aug 2026 · bioRxiv · 0 citations · 55 references
Biology
Read PDF